TECX — Tectonic Therapeutic, Inc.
NASDAQ · Healthcare · Biotechnology
$31.22
+$0.00 (+0.00%)
Tectonic Therapeutic, Inc. (TECX) is a biotechnology company listed on NASDAQ. It is led by Alise S. Reicin M.D., Ph.D., based in 490 Arsenal Way, Watertown, MA, United States, 02472, with about 60 employees. Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Net income was -$54.9M. TECX currently screens at market cap $567.2M.
Use this TECX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TECX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TECX SEC filings page. Lician reads the product cache first so this HTML stays unique to Tectonic Therapeutic, Inc. even when a live quote feed is slow.
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
TECX Key Statistics
Market Cap
$567.21M
Volume
145,070
Previous Close
$37.71
Day Range
$35.76 – $38.85
P/B Ratio
2.46
EPS
-$6.83
Revenue
$0.00
Net Income
-$57.98M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
60
TECX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$57.98M | -$42.82M | -$105.89M | -$119.13M |
| EPS (Diluted) | -$6.83 | -$33.76 | -$2.42 | -$2.78 |
Total Assets
$152.91M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$141.24M
Operating Cash Flow
-$59.08M
Free Cash Flow
$0.00
Tectonic Therapeutic, Inc. Company Information
- President, CEO, Secretary & Director
- Alise S. Reicin M.D., Ph.D.
- Headquarters
- 490 Arsenal Way, Watertown, MA, United States, 02472
- Website
- tectonictx.com
- Phone
- 339 666 3320
- IPO / Founded
- 2018-06-21
- Sector
- Healthcare
- Industry
- Biotechnology